Myriad Genetics, Inc (NASDAQ: MYGN) kicked off on Tuesday, down -4.21% from the previous trading day, before settling in for the closing price of $5.22. Over the past 52 weeks, MYGN has traded in a range of $3.81-$29.30.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded -106.08%. With a float of $87.40 million, this company’s outstanding shares have now reached $92.20 million.
Let’s look at the performance matrix of the company that is accounted for 2700 employees. In terms of profitability, gross margin is 70.01%, operating margin of -14.98%, and the pretax margin is -15.27%.
Myriad Genetics, Inc (MYGN) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Diagnostics & Research Industry. The insider ownership of Myriad Genetics, Inc is 5.19%, while institutional ownership is 102.77%. The most recent insider transaction that took place on Oct 11 ’24, was worth 343,950. In this transaction President and CEO of this company sold 15,000 shares at a rate of $22.93, taking the stock ownership to the 962,378 shares. Before that another transaction happened on Oct 11 ’24, when Company’s Officer proposed sale 15,000 for $22.93, making the entire transaction worth $343,950.
Myriad Genetics, Inc (MYGN) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -106.08% per share during the next fiscal year.
Myriad Genetics, Inc (NASDAQ: MYGN) Trading Performance Indicators
Take a look at Myriad Genetics, Inc’s (MYGN) current performance indicators. Last quarter, stock had a quick ratio of 1.71. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.55.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.12, a number that is poised to hit -0.01 in the next quarter and is forecasted to reach 0.15 in one year’s time.
Technical Analysis of Myriad Genetics, Inc (MYGN)
Myriad Genetics, Inc (NASDAQ: MYGN) saw its 5-day average volume 1.14 million, a negative change from its year-to-date volume of 1.66 million. As of the previous 9 days, the stock’s Stochastic %D was 10.23%.
During the past 100 days, Myriad Genetics, Inc’s (MYGN) raw stochastic average was set at 10.44%, which indicates a significant decrease from 10.75% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.29 in the past 14 days, which was lower than the 0.46 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.97, while its 200-day Moving Average is $12.14. Nevertheless, the first resistance level for the watch stands at $5.26 in the near term. At $5.51, the stock is likely to face the second major resistance level. The third major resistance level sits at $5.65. If the price goes on to break the first support level at $4.86, it is likely to go to the next support level at $4.72. The third support level lies at $4.47 if the price breaches the second support level.
Myriad Genetics, Inc (NASDAQ: MYGN) Key Stats
The company with the Market Capitalisation of 460.89 million has total of 92,177K Shares Outstanding. Its annual sales at the moment are 837,600 K in contrast with the sum of -127,300 K annual income. Company’s last quarter sales were recorded 195,900 K and last quarter income was -100 K.
